EULAR 2019 session recommendations

Session recommendation

EULAR 2019 opening plenary session

Wednesday 12 June, 13:00–14:00, Hall 6, IFEMA – Feria de Madrid, Madrid, Spain.

Featuring inspiring talks and updates from EULAR, in addition to the EULAR Awards.

Session recommendation

Wednesday 12th June, 16:15–17:45, Hall 6, IFEMA – Feria de Madrid, Madrid, Spain.

Chairs – John Isaacs and Thomas Dörner

What to choose: a second TNFI or an alternative class of biologic for patients with JIA who have failed their first TNF. Lianne Kearsley-Fleet
Efficacy and safety of filgotinib for patients with rheumatoid arthritis with inadequate response to methotrexate: FINCH1 primary outcome results. Bernard Combe
Nintedanib reduced decline in forced vital capacity across subgroups of patients with systemic sclerosis-associated interstitial lung disease: data from the SENSCIS trial. Oliver Distler
MiR-34A is a potential therapeutic target in osteoarthritis. Mohit Kapooor
A systematic review and meta-analysis assessing gastrointestinal, liver, renal and cardiovascular adverse events of paracetamol. Jaspreet Kaur
Less is more: analysing the impact of repeated antinuclear antibody testing. Ai Li Yeo
Predicting severe infection in repeat cycles of rituximab and effects of hypogammaglobulinaemia for the treatment of rheumatic and musculoskeletal diseases. Md Yuzaiful Md Yusof
Do MRI-detected erosions in patients with clinically suspect arthralgia predict progression to rheumatoid arthritis? A longitudinal study. Fenne Wouters
Randomised, double-blind, placebo-controlled, multiple-dose, Phase 2b study to demonstrate the safety and efficacy of tildrakizumab, a high-affinity anti–interleukin-23p19 monoclonal antibody, in patients with active psoriatic arthritis. Philip Mease

Session recommendation

Thursday 13th June, 10:15–11:45, Hall 6, IFEMA – Feria de Madrid, Madrid, Spain.

WIN: De-convoluting the complexities of SLE – recent insights into the pathogenesis – Mary K. Crow

HOT: Novel paradigms in the management of SLE – Thomas Dörner

Session recommendation

Friday 14th June, 15:30–17:00, N101/N102, IFEMA – Feria de Madrid, Madrid, Spain.

Chairs – Lovro Lamot and Sebastian Vastert

Pathophysiology informing therapy in MAS: what we’ve learned in paediatric practice. Alexei Grom
Calming the storm in children. Anna Carin Horne
Calming the storm in adult MAS/HLH in rheumatic disorders. Jan van Laar
Comparison of serum cytokine profile in macrophage activation syndrome among different background rheumatic diseases in children. Mao Mizuta
PLCGAMMA2/TMEM178 dependent pathway in myeloid cells modulates the pathogenesis of cytokine storm syndrome. Robert Faccio

Session recommendation

Saturday 15th June, 09:00–10:50, Hall 7A, IFEMA – Feria de Madrid, Madrid, Spain.

Chairs – Thomas Huizinga and Ulf Müller-Ladner

Update on EULAR recommendations for the management of SLE. Antonis Fanouriakis
Sjögren’s management recommendations 2019. Manuel Ramos-Casals
Management of adult APS: recommendations from an EULAR task force. Maria Tektonidou
Update of the EULAR recommendations large vessel vasculitis management. Bernhard Hellmich
Update of the EULAR recommendation on PsA. Laure Gossec
Update of the EULAR recommendations on RA. Josef S. Smolen

Session recommendation

Saturday 15th June, 13:45–14:45, Hall 7A, IFEMA – Feria de Madrid, Madrid, Spain.

Chairs – Thomas Dörner and John Isaacs